More Waves to come on stereopure antisense oligo tech
With Wave’s first readouts underwhelming, it’ll look to upcoming HD data to validate its founding hypothesis
Though the first clinical readouts from Wave’s antisense oligo platform disappointed investors, the company thinks it can parlay the learnings into improved efficacy. 2020 will offer more data readouts to support or refute the company’s hypothesis that stereopure oligos will have better efficacy and safety than the standard oligo format, which involves random mixtures of molecules with identical sequences, but different 3D conformations.
The next chances to make the case will come from a higher dose and a second version of its Huntington disease therapy, both of which target the mutant version of the huntingtin protein (HTT).
Wave Life Sciences Ltd. (NASDAQ:WVE) was founded in 2012 to design and manufacture stereopure nucleic acids. Because synthetic oligonucleotides contain many chiral centers where nucleotides can adopt one of two configurations, there are hundreds of thousands of different 3D arrangements each oligomer can adopt.
Wave’s technology creates a single configuration for any oligo sequence, optimized for purpose -- the idea being that the different conformations are vulnerable to ADME-PK issues that reduce efficacy